Shraddha Tuladhar

Dr. Shraddha Tuladhar


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
STShraddha Tuladhar
Shraddha Tuladhar
JKJoshua A. Kochanowsky
Joshua A. Kochanowsky
ABApoorva Bhaskara
Apoorva Bhaskara
YGYarah Ghotmi
Yarah Ghotmi
SCSambamurthy Chandrasekaran
Sambamurthy Chandrasekaran
AKAnita A. Koshy
Anita A. Koshy
Toxoplasma gondii is an intracellular parasite that persistently infects the CNS and that has genetically distinct strains which provoke different acute immune responses. How differences in the acute immune response affect the CNS immune response is unknown. To address this question, we used two persistent Toxoplasma strains (type II and type III) and examined the CNS immune response at 21 days post infection (dpi). Contrary to acute infection studies, type III-infected mice had higher numbers of total CNS T cells and macrophages/microglia but fewer alternatively activated macrophages (M2s) and regulatory T cells (Tregs) than type II-infected mice. By profiling splenocytes at 5, 10, and 21 dpi, we determined that at 5 dpi type III-infected mice had more M2s while type II-infected mice had more pro-inflammatory macrophages and that these responses flipped over time. To test how these early differences influence the CNS immune response, we engineered the type III strain to lack ROP16 (IIIΔrop16), the polymorphic effector protein that drives the early type III-associated M2 response. IIIΔrop16-infected mice showed a type II-like neuroinflammatory response with fewer infiltrating T cells and macrophages/microglia and more M2s and an unexpectedly low CNS parasite burden. At 5 dpi, IIIΔrop16-infected mice showed a mixed inflammatory response with more pro-inflammatory macrophages, M2s, T effector cells, and Tregs, and decreased rates of infection of peritoneal exudative cells (PECs). These data suggested that type III parasites need the early ROP16-associated M2 response to avoid clearance, possibly by the Immunity-Related GTPases (IRGs), which are IFN-γ- dependent proteins essential for murine defenses against Toxoplasma. To test this possibility, we infected IRG-deficient mice and found that IIIΔrop16 parasites now maintained parental levels of PECs infection. Collectively, these studies suggest that, for the type III strain, rop16III plays a key role in parasite persistence and influences the subacute CNS immune response. Toxoplasma is a ubiquitous intracellular parasite that establishes an asymptomatic brain infection in immunocompetent individuals. However, in the immunocompromised and the developing fetus, Toxoplasma can cause problems ranging from fever to chorioretinitis to severe toxoplasmic encephalitis. Emerging evidence suggests that the genotype of the infecting Toxoplasma strain may influence these outcomes, possibly through the secretion of Toxoplasma strain-specific polymorphic effector proteins that trigger different host cell signaling pathways. While such strain-specific modulation of host cell signaling has been shown to affect acute immune responses, it is unclear how these differences influence the subacute or chronic responses in the CNS, the major organ affected in symptomatic disease. This study shows that genetically distinct strains of Toxoplasma provoke strain-specific CNS immune responses and that, for one strain (type III), acute and subacute immune responses and parasite survival are heavily influenced by a polymorphic parasite gene (rop16III).

2 February 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
COCarla O’REilly
Carla O’REilly
STShraddha Tuladhar
Shraddha Tuladhar
PNPhuong Nguyen
Phuong Nguyen
HSHeather Sheppard
Heather Sheppard
SKSelene C. Koo
Selene C. Koo
CDChristopher DeRenzo
Christopher DeRenzo
Purpose: Chimeric antigen receptor (CAR) T-cell therapy offers a promising approach to improve outcomes for patients with relapsed, refractory, or metastatic osteosarcoma. However, novel target antigens are needed to overcome obstacles limiting CAR T-cell efficacy against osteosarcoma and other solid tumors. Leucine-rich repeat-containing 15 (LRRC15) has been identified as a promising target in patients with osteosarcoma. Given these findings, we aimed to develop LRRC15-CAR T cells and evaluate their antitumor activity and safety in preclinical models. Experimental Design: We evaluated LRRC15 expression in normal tissues and pediatric solid tumors using gene expression and immunohistochemical (IHC) approaches. We generated LRRC15-CAR T cells using a binding domain that recognizes human and murine LRRC15 and evaluated their specificity, antitumor activity, and safety in preclinical studies. Results: Gene expression analysis demonstrated limited Lrrc15 expression in normal tissues and high expression in osteosarcoma, which was confirmed at the protein level by IHC staining of primary pediatric osteosarcoma tumors. In vitro, LRRC15-CAR T cells demonstrated specificity and cytotoxicity against LRRC15-positive targets. In vivo, LRRC15-CAR T cells exhibited antitumor activity in both human xenograft and immunocompetent murine osteosarcoma models, leading to significantly increased survival compared with controls. Finally, comprehensive toxicity analysis demonstrated a positive safety profile of intravenously administered LRRC15-CAR T cells. Conclusions: LRRC15-CAR T cells exert anti-osteosarcoma activity while maintaining a positive safety profile. These promising findings support the clinical translation of LRRC15-CAR T cells for patients with osteosarcoma and potentially other LRRC15-positive solid tumors.

21 May 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
STShraddha Tuladhar
Shraddha Tuladhar
JKJoshua A. Kochanowsky
Joshua A. Kochanowsky
ABApoorva Bhaskara
Apoorva Bhaskara
YGYarah Ghotmi
Yarah Ghotmi
AKAnita A. Koshy
Anita A. Koshy
Toxoplasma gondii is an intracellular parasite that persistently infects the CNS and that has genetically distinct strains which provoke different acute immune responses. How differences in the acute immune response affect the CNS immune response is unknown. To address this question, we used two persistent Toxoplasma strains (type II and type III) and examined the CNS immune response at 21 days post infection (dpi). Contrary to acute infection studies, type III-infected mice had higher numbers of total CNS T cells and macrophages/microglia but fewer alternatively activated macrophages (M2s) and regulatory T cells (Tregs) than type II-infected mice. By profiling splenocytes at 5, 10 and 21 dpi, we determined that at 5 dpi type III-infected mice had more M2s while type II-infected mice had more classically activated macrophages (M1s) and these responses flipped over time. To test how these early differences influence the CNS immune response, we engineered the type III strain to lack ROP16 (IIIΔ rop16 ), the polymorphic effector protein that drives the type III-associated M2 response. IIIΔ rop16 -infected mice showed a type II-like neuroinflammatory response with fewer infiltrating T cells and macrophages/microglia and more M2s and an unexpectedly low CNS parasite burden. At 5 dpi, IIIΔ rop16 -infected mice showed a mixed inflammatory response with more M1s, M2s, T effector cells, and Tregs, and decreased rates of infection of peritoneal exudative cells (PECs). These data suggested that type III parasites need the early ROP16-associated M2 response to avoid clearance, possibly by the Immunity-Related GTPases (IRGs), IFN-γ dependent proteins essential for murine defenses against Toxoplasma . To test this possibility, we infected IRG-deficient mice and found that IIIΔ rop16 parasites now maintained parental levels of PECs infection. Collectively, these studies suggest that, for the type III strain, rop16 III plays a key role in parasite persistence and influences the sub-acute CNS immune response. Author Summary: Toxoplasma is a ubiquitous intracellular parasite that establishes an asymptomatic brain infection in immunocompetent individuals. However, in the immunocompromised and the developing fetus, Toxoplasma can cause problems ranging from fever to chorioretinitis to severe toxoplasmic encephalitis. Emerging evidence suggests that the genotype of the infecting Toxoplasma strain may influence these outcomes, possibly through the secretion of Toxoplasma strain-specific polymorphic effector proteins that trigger different host cell signaling pathways. While such strain-specific modulation of host cell signaling has been shown to affect acute immune responses, it is unclear how these differences influence the sub-acute or chronic responses in the CNS, the major organ affected in symptomatic disease. This study shows that genetically distinct strains of Toxoplasma provoke strain-specific CNS immune responses and that, for one strain (type III), the acute and sub-acute immune responses and parasite survival are heavily influenced by a polymorphic parasite gene ( rop16 III ).

17 June 2026
Verified
Other
Open access
COCarla O’REilly
Carla O’REilly
STShraddha Tuladhar
Shraddha Tuladhar
PNPhuong Nguyen
Phuong Nguyen
HSHeather Sheppard
Heather Sheppard
SKSelene C. Koo
Selene C. Koo
CDChristopher DeRenzo
Christopher DeRenzo
LRRC15-CAR T cells exhibit transient antitumor activity and enhance survival in a bulky orthotopic limb osteosarcoma model

17 June 2026
Verified
Other
Open access
COCarla O’REilly
Carla O’REilly
STShraddha Tuladhar
Shraddha Tuladhar
PNPhuong Nguyen
Phuong Nguyen
HSHeather Sheppard
Heather Sheppard
SKSelene C. Koo
Selene C. Koo
CDChristopher DeRenzo
Christopher DeRenzo
LRRC15-CAR T cell persistence in the OS152 orthotopic osteosarcoma model

17 June 2026
Verified
Other
Open access
COCarla O’REilly
Carla O’REilly
STShraddha Tuladhar
Shraddha Tuladhar
PNPhuong Nguyen
Phuong Nguyen
HSHeather Sheppard
Heather Sheppard
SKSelene C. Koo
Selene C. Koo
CDChristopher DeRenzo
Christopher DeRenzo
Pre-infusion healthy donor T cell characteristics for in vivo studies